Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

X
Drug Profile

Delolimogene mupadenorepvec - Lokon Pharma

Alternative Names: LOAd 703

Latest Information Update: 20 Jan 2025

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Lokon Pharma
  • Developer Lokon Pharma; Uppsala University
  • Class Antineoplastics; Gene therapies; Immunotherapies; Oncolytic viruses
  • Mechanism of Action 4-1BB ligand expression stimulants; CD40 ligand expression stimulants; Cell death stimulants; Dendritic cell stimulants; Immunologic cytotoxicity; Macrophage stimulants; Natural killer cell stimulants; T-cell receptor gene stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Cancer; Malignant melanoma
  • Research Breast cancer; Sarcoma
  • No development reported B-cell lymphoma; Multiple myeloma

Most Recent Events

  • 13 Sep 2024 Adverse events and efficacy data from a phase-I/II trial in Malignant melanoma presented at the 49th European Society for Medical Oncology Congress (ESMO-2024), ,
  • 13 Sep 2024 Adverse events and efficacy data from a phase-I/II trial in Cancer presented at the 49th European Society for Medical Oncology Congress (ESMO-2024), ,
  • 28 Sep 2023 No recent reports of development identified for preclinical development in B-cell lymphoma in Sweden (Intratumoural, Injection)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days